GGrantIndex
← Leaderboards

Gregory A Jicha

University Of Kentucky

Google Scholar ↗PubMed ↗ORCID ↗
$17,898,620
Attributed
$27,940,532
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.6M · FY2007–25
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$27,940,532 · 11

By mechanism

R01$9,130,831 · 4
P30$7,846,208 · 2
UF1$6,120,000 · 1
UH3$3,405,574 · 1
UH2$1,427,419 · 1
M01$10,500 · 2

Top collaborators

Most similar at University Of Kentucky

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposDementiaS DiseaseBiological MarkersClinical TrialsBrainElderlyUniversitiesKentuckyCohortImpaired CognitionPathologyCognitiveResearch PersonnelAutopsyImageDesignPre-ClinicalAffectPharmaceutical PreparationsMultidisciplinarySuccessBaseCognition

Grant awards (40)

Core B: University of Kentucky Alzheimer's Disease Core Center$955,337
P30 · FY2025 · AG · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArT–HS)$659,649
R01 · FY2025 · AG · contact PI
Core B: University of Kentucky Alzheimer's Disease Core Center$921,025
P30 · FY2024 · AG · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArT–HS)$703,505
R01 · FY2024 · AG · contact PI
The University of Kentucky MarkVCID Biomarker Validation Cohort: Development of a Toolbox to Advance VCID Interventional Studies$3,672,000
UF1 · FY2023 · NS · contact PI
Core B: University of Kentucky Alzheimer's Disease Core Center$947,257
P30 · FY2023 · AG · contact PI
Core B: University of Kentucky Alzheimer's Disease Core Center$975,595
P30 · FY2022 · AG · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArT–HS)$716,551
R01 · FY2022 · AG · contact PI
The University of Kentucky MarkVCID Biomarker Validation Cohort: Development of a Toolbox to Advance VCID Interventional Studies$2,448,000
UF1 · FY2021 · NS · contact PI
Core B: University of Kentucky Alzheimer's Disease Core Center$979,876
P30 · FY2021 · AG · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging$740,936
R01 · FY2021 · AG · contact PI
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$1,125,772
UH3 · FY2020 · NS
Core B: Clinical Core$670,154
P30 · FY2020 · AG · contact PI
INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study$254,575
R01 · FY2020 · AG
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$1,135,298
UH3 · FY2019 · NS
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArT–HS)$763,006
R01 · FY2019 · AG · contact PI
Core B: Clinical Core$599,241
P30 · FY2019 · AG · contact PI
INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study$368,857
R01 · FY2019 · AG
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$1,144,504
UH3 · FY2018 · NS
Core B: Clinical Core$599,241
P30 · FY2018 · AG · contact PI
INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study$472,076
R01 · FY2018 · AG
INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study$99,445
R01 · FY2018 · AG
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$707,397
UH2 · FY2017 · NS
Core B: Clinical Core$599,241
P30 · FY2017 · AG · contact PI
INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study$462,821
R01 · FY2017 · AG
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$720,022
UH2 · FY2016 · NS
Core B: Clinical Core$599,241
P30 · FY2016 · AG · contact PI
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$537,355
R01 · FY2016 · AG · contact PI
Early Detection and Prevention of Mild Cognitive Impairment due to Cerebrovascular Disease$380,785
R01 · FY2016 · NR · contact PI
INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study$352,153
R01 · FY2016 · AG
Early Detection and Prevention of Mild Cognitive Impairment due to Cerebrovascular Disease$369,361
R01 · FY2015 · NR · contact PI
Early Detection and Prevention of Mild Cognitive Impairment due to Cerebrovascular Disease$144,692
R01 · FY2015 · NR · contact PI
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$44,229
R01 · FY2015 · AG · contact PI
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$499,395
R01 · FY2014 · AG · contact PI
Early Detection and Prevention of Mild Cognitive Impairment due to cerebrovascula$376,976
R01 · FY2014 · NR · contact PI
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$486,839
R01 · FY2013 · AG · contact PI
Early Detection and Prevention of Mild Cognitive Impairment due to cerebrovascula$360,985
R01 · FY2013 · NR · contact PI
Early Detection and Prevention of Mild Cognitive Impairment due to cerebrovascula$336,640
R01 · FY2012 · NR · contact PI
ANTI-OXIDANT TREATMENT IN AD$10,042
M01 · FY2007 · RR · contact PI
EFFECTS OF DHA$458
M01 · FY2007 · RR · contact PI